ArticleAnnals of nuclear medicine2018
Low levels of PSMA expression limit the utility of
Article in Annals of nuclear medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.International journal of molecular sciences · 2019Pooled it
- Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targetedAnnals of nuclear medicine · 2019Trial
- Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [Molecular imaging and biology · 2019Trial
- Comparison of [Molecular imaging and biology · 2026Article
- Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Distribution of prostate specific membrane antigen (PSMA) on PET-MRI in patients with and without ovarian cancer.Abdominal radiology (New York) · 2023Article
- Head-to-head comparisons ofInternational urology and nephrology · 2023Article
- VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder.BMC urology · 2022Article
- PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?Journal of clinical medicine · 2022Review
- Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.Cancers · 2022Review
- Feasibility of [European journal of nuclear medicine and molecular imaging · 2022Article
- PSMA expression on neovasculature of solid tumors.Histology and histopathology · 2020Review
- Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.Nature reviews. Urology · 2020Review
- Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.Journal of cancer research and clinical oncology · 2020Article
- The use ofEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Activities for the Development of Targeted Radionuclide Therapy in Japan.Nuclear medicine and molecular imaging · 2019Article
- Antibody-Drug Conjugates in Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo explore the clinical utility of PSMA-targeted
methodsThree patients with metastatic urothelial carcinoma were imaged with
results
conclusionThe relatively scant expression of PSMA by urothelial carcinoma likely limits the utility of PSMA-targeted PET imaging of this malignancy. Future research efforts should focus on the development of other molecularly targeted imaging agents for urothelial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.